By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Asterias Biotherapeutics 

230 Constitution Drive

Menlo Park  California  94025  U.S.A.
Phone: 650-433-2992 Fax: n/a



Company News
Asterias Biotherapeutics To Report Second Quarter Results On August 10, 2015 7/30/2015 12:39:32 PM
Asterias Biotherapeutics Added To Russell 2000, Russell 3000, Russell Global And Russell Microcap Indexes 6/30/2015 7:23:04 AM
Preliminary Reconstitutions Of Russell 3000, Russell Global And Russell Microcap Indexes Include Asterias Biotherapeutics 6/15/2015 7:42:29 AM
Asterias Biotherapeutics Announces First Patient Treated In Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 6/8/2015 9:11:01 AM
Positive New, Long-Term Follow-Up Data Of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival In Patients With High-Risk Acute Myelogenous Leukemia (AML) 6/1/2015 7:47:56 AM
Asterias Biotherapeutics Receives $11.7 Million In Proceeds From Exercise Of Warrants 5/26/2015 7:33:50 AM
Asterias Biotherapeutics Announces Availability Of Abstract With Phase 2 Clinical Data On Cancer Vaccine AST-VAC1 In Acute Myelogenous Leukemia (AML) 5/14/2015 6:22:22 AM
Asterias Biotherapeutics Reports First Quarter Results 5/8/2015 6:39:40 AM
Asterias Biotherapeutics Promotes Edward Wirth, M.D., Ph.D. To Chief Medical Officer 5/8/2015 6:20:29 AM
Asterias Biotherapeutics To Host Investor Meeting To Review Clinical Development Strategy For AST-OPC1 In Spinal Cord Injury 5/7/2015 7:58:33 AM